Zephyrnet Logo

Tag: arthritis

Top 25 Mobile App Development Companies in The USA

List of Mobile App Development Companies in USA, San Francisco, California Top 25 Mobile App Development Companies in the USA Smart Phones have tremendously changed the...

How to Make CBD Tea and Six Ingredients You Need To Try

CBD is quickly becoming a simple and popular way to alleviate pain, even among those who have never experimented with cannabis before. Learning how...

Does Cannabis Help With Bone Health?

The skeletal system is an essential of the human anatomy. We need our skeletal system to stand erect, to walk properly and function optimally....

How To Introduce CBD To Your Pet: Exclusive Interview With Scott Mazza, COO Of Vitality CBD

Did you know that one in five dogs have canine arthritis?While this disease commonly affects older dogs and larger breeds like German shepherds, Labs, Golden retrievers and mixtures thereof,...

CBD Oil And Other Best Oils For Massage

View the original article about CBD Oil And Other Best Oils For Massage at How To Buy CBD Oils.CBD-infused massage oils have gained huge...

Targeting the activity of T cells by membrane surface redox regulation for cancer theranostics

Melero, I., Castanon, E., Alvarez, M., Champiat, S. & Marabelle, A. Intratumoural administration and tumour tissue targeting of cancer immunotherapies. Nat. Rev. Clin. Oncol....

I tried ‘mad honey,’ but actually felt pretty happy

I tried ‘mad honey,’ but actually felt pretty happy | Leafly ...

ADDING MULTIMEDIA MyMD Pharmaceuticals® to Present Data on Oral TNF-a Inhibitor MYMD-1® at the British Society for Immunology (BSI) Congress 2022

BALTIMORE–(BUSINESS WIRE)–MyMD Pharmaceuticals, Inc.® (Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage biopharmaceutical company developing groundbreaking therapies for the treatment of serious and...

Nanotechnology strategy shows promise for treating autoimmune disease

Dec 01, 2022 (Nanowerk News) Scientists at Scripps Research have reported success in initial tests of a new, nanotech-based strategy against autoimmune diseases. The scientists,...

Cherry weed strains: 6 cherry-flavored weed strains for a mouth-watering smoke

What is it about cherries that are so charming? From cherry pies to cherry slushies to cherry blossoms blooming in the springtime, cherries are...

How to Choose the Best CBD Oil for Your Body and Lifestyle

The popularity of CBD oil is increasing. This is due to the continuous legalization of cannabis use, for both medical and recreational use. As...

Metoject Subcutaneous Injection Syringe (Methotrexate) Launched In Japan For Rheumatoid Arthritis

TOKYO, Nov 16, 2022 - (JCN Newswire) - Eisai Co., Ltd. and nippon medac Co., Ltd., a subsidiary of medac Gesellschaft fur klinische Spezialpraparate mbH announced today that they have launched the anti-rheumatic agent "Metoject Subcutaneous Injection 7.5mg syringe 0.15mL, 10mg syringe 0.20mL, 12.5mg syringe 0.25mL and 15mg syringe 0.30mL" (methotrexate, "MTX") in Japan with the indication of rheumatoid arthritis. nippon medac obtained the manufacturing and marketing approval of Japan's first self-administrable subcutaneous injection formulation of MTX, a first line option for the treatment of rheumatoid arthritis, on September 26, 2022. The product is published to Japan's National Health Insurance Drug Price List, today.


The approval of Metoject in Japan is based on the results of a Phase III clinical trial (MC-MTX.17/RA) conducted in Japan by nippon medac to compare the efficacy and safety of Metoject with that of oral MTX, which consisted of a double-blind phase and an extension phase. Based on the license agreement signed by Eisai and medac GmbH in May 2019, nippon medac will hold the marketing authorization of Metoject, while Eisai will be responsible for product distribution of Metoject in Japan.

"Eisai has established a solid franchise and has extensive sales experience in the rheumatoid arthritis area in Japan. By adding Metoject to Eisai's product lineup, we are now able to contribute to rheumatoid arthritis patients in a wide range of stages from the early stages of treatment," said Terushige Iike, Senior Vice President of Eisai and President of Eisai Japan. "We are committed to making further contributions to address the diversified needs of, and increase the benefits provided to, rheumatoid arthritis patients."

"Metoject is the first drug for which nippon medac obtained its manufacturing and marketing approval in Japan. It is also the first self-administrable MTX subcutaneous injection formulation for rheumatoid arthritis in Japan," said Hirohisa Iriyama, Representative Director and President of nippon medac. "Although the drug is already widely used overseas, Eisai, which has extensive experience in this area, has been entrusted with the marketing of the drug in Japan, where there are an estimated 700,000 to 800,000 rheumatoid arthritis patients1, allowing us to bring the drug to them as a new treatment option. Nippon medac will continue to make further contributions in this area."

For more information, visit www.eisai.com/news/2022/news202278.html.

Media Inquiries:

Eisai Co., Ltd.
Public Relations Department
TEL: +81-(0)3-3817-5120

nippon medac Co., Ltd.
Ueno
TEL: +81-(0)3-6661-6270


Copyright 2022 JCN Newswire. All rights reserved. www.jcnnewswire.comEisai Co., Ltd. and nippon medac Co., Ltd. announced today that they have launched the anti-rheumatic agent "Metoject Subcutaneous Injection 7.5mg syringe 0.15mL, 10mg syringe 0.20mL, 12.5mg syringe 0.25mL and 15mg syringe 0.30mL" (methotrexate, "MTX") in Japan.

Latest Intelligence

spot_img
spot_img